Protein concentration was estimated spectrophotometrically from optical density (OD) at 280 and 260 nm or by the biuret reaction, albumin with bromcresol green and PSA by radioimmunoassay. Concentrations of IGF-I and -II in the ejaculates were determined by displacement radioimmunoassay (RIA) after extraction with acid-ethanol, neutralisation and cryoprecipitation (9, 10) . Thus, IGF-I was determined using a polyclonal rabbit anti-IGF-I antiserum (Biogenesis, Poole, UK), which showed 0.054% cross-reactivity with IGF-II at 50% inhibition of 125 I-IGF-I tracer binding. Sufficient IGF-II (ICN Biomedicals Inc., Aurora, USA) was added to the reaction mixture to release IGF-I from any IGFBP carried through the extraction procedure and allow reaction with the reagent antiserum. Conversely, IGF-I (ICN Biomedicals Inc., Aurora, USA) could be included in the assay for IGF-II where a mouse monoclonal anti-IGF-II antibody (Biogenesis, Poole, UK) was used as the reagent, because crossreactivity with IGF-I at 50% inhibition of 125 I-IGF-II tracer binding was 0.4%. Samples of the respective reference IGF preparations (WHO 87/518 and WHO 96/538) were included in each test series. Recovery of added ligand was 88.2 ± 12.5% (n = 9) in the IGF-I assay and 86.3 ± 5.2% (n = 7) in the IGF-II assay. Interassay and intrassay coefficients of variation were below 12% and 10% respectively. When human IGFBP-2 was tested in the IGF-I RIA instead of IGF-I standards, a parallel inhibition curve 46-fold less sensitive was obtained.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of seminal plasma was performed as previously described for blood serum (11, 12) . Proteins were electrotransferred to nitrocellulose membranes (0.45 mm, Schleicher and Schuell, Einbeck, Germany), followed by autoradiography after incubation with 125 I-IGF-I of specific activity approximately 36 MBq/nmol. Protein bands were putatively identified according to the mobility of reference standards: transferrin (80 kD), bovine serum albumin (BSA, 66 kD), ovalbumin (OA, 45 kD), glyceraldehyde-3-phosphate dehydrogenase (36 kD), carbonic anhydrase (29 kD), chymotrypsin (24 kD). Human IGFBP-2 (34 kD, GroPep Ltd., Adelaide, Australia) was also used as a reference standard.
Ejaculate samples (0.5 mL) were subjected to molecular size chromatography on a column (31.5 × 0.86 cm) of Sephadex G-75 (bed volume 27 mL) with 1 mol/L acetic acid or 1 mol/L NaCl in 0.05 mol/L phosphate buffer (PB; pH 7.5) as the eluant. Protein fractions were also separated on a Sephacryl S-300 column (90 × 1.5 cm; bed volume 160 mL) calibrated with blue dextran (2000 kD), OA and insulin (6 kD). Protein concentration in eluate fractions was estimated spectrophotometrically from the optical density at 280 nm. The position of IGF and/or IGFBP was detected by elution in the presence of 125 I-IGF or by direct IGF-I RIA without previous acid-ethanol extraction. Fractions containing IGFBP were bulked, reduced in volume by centrifugation through a Millipore filter (10,000 kD cut-off) or by Amicon (UM-10) ultrafitration. They were then separated from glycoproteins by chromatography on Concanavalin-A Sepharose (10 × 0.6 cm; bed volume 5 mL) using 0.14 mol/L TRIS buffer (pH 7.2) with appropriate mineral supplements as eluant.
Data were statistically analysed using the MSTATC (U.S.A.) programme. Values obtained were checked for normal distribution within groups and subjected to square root or logarithmic transformation, as appropriate, before analysis by parametric methods. Student's t-test for the significance of differences between two groups was preceded by an F-test for equality of variance. Probability values less than 0.05 were considered statistically significant.
Results
Mean ejaculate volume was 3.3 mL (range 1' 6 mL). The number of motile spermatozoa (0 '165 million/mL; mean 49; median 39) was highly correlated (r = 0.95; P < 0.001) with total number (0 '300 million/mL; mean 88; median 83). Concentrations of IGF-I ranged from 2.7 to 29.7 nmol/L (mean 9.6; median 13.5 nmol/L). IGF-II levels were slightly higher, ranging from 5.7 to 39.0 nmol/L (mean 16.0; median 13.5 nmol/L), and positively correlated with IGF-I levels (r = 0.584; P < 0.001).
Viscosity was increased moderately (grade 2) in six samples and greatly (grade 3) in four more. When the results for these ten ejaculates were grouped and compared with those for the twenty samples with normal viscosity (Table I) , it was apparent that the mean concentration of IGF-I (13.8 nmol/L) was significantly higher in the former than in the latter group (7.5 nmol/ L). Mean IGF-II concentration was slightly but not significantly higher. Values for t were statistically significant whether the data were mathematically transformed to eliminate skewedness and kurtosis or not.
The electrophoretic profile of seminal plasma showed dominant proteins at 80, 66 and 30 kD (Figure 1a) consistent with the presence of albumin (21.2 mg/mL) and PSA (1.8 mg/mL) as well as lactoferrin (13) . The IGFBP profile for several samples is shown in Figure 1b in comparison with human serum. Bands with the same mobility as IGFBP-2 (34 kD) were dominant, putative IGFBP-4 (24 kD) bands were present but faint, while the IGFBP-3 doublet (40 ' 45 kD) characteristic for serum was absent.
While acid chromatography of blood serum on Sephadex G-75 clearly separated free IGF (7 kD) from IGFBP (25 ' 40 kD) nearly all IGF/IGFBP in seminal plasma remained associated with higher molecular mass proteins (Figure 2) . Elution through Sephacryl S-300 with neutral PB containing 0.05 mol/L NaCl gave four main OD peaks, the second containing PSA. Practically all IGF/IGFBP eluted in a broad irregular peak before PSA (Figure 3a) . However, increasing the salt concentration to 1 mol/L concentrated most IGF/ IGFBP into a sharp peak eluting at the position expected for IGF/IGFBP binary complexes (Figure 3b) without much modification to the OD elution profile. Chromatography of the IGF/IGFBP containing fractions on ConA removed glycoproteins, including IGFBP-4, and the presence of IGFBP-2 in the non-bound fraction was confirmed by SDS-PAGE and autoradiography of the ligand blot. However, purification from enzymes, such as PSA, was not complete and separation of IGFBP from the higher molecular mass complexes appeared to facilitate degradation. While subsequent elution of the Con-A non-bound fraction on Sephadex G-75 showed IGF-equivalents in higher molecular mass complexes, as well as at the positions expected for IGFBP-2 and IGF-I, the yield was very low and OD values indicated extensive degradation to small molecular mass compounds. This was not prevented by including SDS, high zinc concentrations (specific PSA inhibitor) or EDTA in the media used.
Discussion
The IGF-I levels found in human ejaculates in this study are of the same order as those recorded Concentrations of IGF-II were of the same order and positively correlated with those for IGF-I. While boar and bull seminal plasma also contain similar amounts of each IGF (15, 17) , an early study reported much higher IGF-II concentrations in human seminal plasma (4) . IGF-II is synthesised in the prostate gland largely in the high molecular mass (15 kD) form (18, 19) . The total molar sum of IGF ligand ranged from 9 to 61 nmol/L in our subjects. This is much less than the reported concentration of IGFBP-2 (355 nmol/L) (6) . It is probable that the high IGF-II level previously reported for human seminal plasma was actually IGFBP-2 (4). We have found that IGFBP will give standard inhibition curves in both IGF RIA. In our study, including the contraligand in all tests (displacement RIA) prevented interference by IGFBP carried through the extraction procedure. This was not done in the early study (4) .
The semen IGFBP profile appears to be species specific as IGFBP-2 and -5 were found in equine, IGFBP-3, -4 and -5 in bovine and IGFBP-2 and -4, plus IGFBP-3 fragments in human seminal plasma (1, 5, 7, 15, 20) but quantitative data are rare. Both IGFBP-2 and -4 are produced by the prostate gland, which also secretes acid and neutral proteases that can rapidly degrade these IGFBPs (8, 18, 21'23) . Degradation appears to be limited by various broad-spectrum protease inhibitors, such as a 2 -macroglobulin (a 2 M), which is both present in seminal plasma and has been shown to bind IGFBP-1 without affecting IGF-binding (1, 24) . Since IGFBP-1 and -2 share many structural similarities, it may be supposed that some seminal plasma IGFBP-2 may be bound to a 2 M. However, IGFBP-2 has been shown to bind to the glycosoaminoglycans (GAG), chondroitin-4 and -6-sulphate (CS), keratan sulphate and heparin, as well as the proteoglycan aggrecan (25) . This binding, which reduced the affinity for IGF-I, could be inhibited by high salt concentrations. Since, normal human seminal plasma contains proteoglycan and several GAGs including CS-C, hyaluronic acid and heparitin sulphate (26, 27) and we have shown that IGFBP/IGF activity is moved from high molecular mass complexes by 1 mol/L NaCl, it appears that most seminal plasma IGFBP-2 is bound in this way without IGF ligand. If it is assumed that all apparent 'IGF-I' eluting in high molecular mass complexes during column chromatography was actually IGFBP-2 then, using the factor 46 found for pure IGFBP-2 in the IGF-I RIA, it may be estimated that our human ejaculates contained from 15 to 50 mg/L. This overestimate is not much higher than the value of 11.1 ± 5.1 mg/L recorded by Blum et al. (6) and confirms the molar excess of IGFBP-2 in human seminal plasma.
While IGFBP-2 is primarily regarded as a protein which inhibits IGF action, protecting the ligands from degradation but preventing them from acting on the specific receptor, independent actions affecting cell adhesion, migration and proliferation through reaction of the RGD-motif with a 2 b 1 -integrin have been reported (28) . Serum IGFBP-2 levels may be elevated in a variety of human malignancies including active prostate carcinoma but not in benign prostate hyperplasia (29, 30) and over-expression of IGFBP-2 has been associated with an increased proliferation rate in some cancer cell lines (31) . The functions of IGF-II and IGFBP-2 in human seminal plasma are not at present known. On the other hand, many authors have concluded that IGF-I has a role in fertility, particularly in connection with normal maturation and motility of the spermatozoa (1 ' 3, 14, 32) .
Acknowledgements: This work was supported by the Ministry of Science, Technology and Development of Serbia, project 1504: Glycobiological aspects of physiological and pathophysiological processes.
